Metabolic Disease
Celltrion Inc. includes type 2 diabetes mellitus within its clinical research portfolio, with interest in treatment strategies for patients who have inadequate glycemic control despite established oral therapy. The sponsor’s work in this area reflects attention to combination approaches involving antihyperglycemic agents and broader management of metabolic disorders.
- Type 2 diabetes mellitus
- Glycemic control
- Combination therapy
Its diabetes-focused studies align with ongoing interest in improving treatment options for chronic endocrine and metabolic disease.
Neurology and Demyelinating Disease
The sponsor is active in multiple sclerosis research, particularly relapsing-remitting multiple sclerosis, with a therapeutic focus on immune-mediated central nervous system disease. This area highlights involvement in treatments aimed at controlling neuroinflammation and disease activity in demyelinating disorders.
- Multiple sclerosis
- Relapsing-remitting multiple sclerosis
- Demyelinating disease
Research in this field reflects interest in therapies used for chronic autoimmune neurological conditions.
Oncology
Celltrion’s oncology portfolio spans melanoma, non-small cell lung cancer, and multiple myeloma, covering both solid tumors and hematologic malignancy. The sponsor’s studies address patients with metastatic disease, adjuvant cancer treatment, and relapsed or refractory malignancies.
- Melanoma
- Non-small cell lung cancer
- Multiple myeloma
This therapeutic area includes interest in immuno-oncology and targeted cancer treatment across different tumor types.
Rheumatology and Autoimmune Inflammation
The sponsor is engaged in rheumatoid arthritis and plaque psoriasis research, both of which are driven by chronic immune-mediated inflammation. These studies point to therapeutic interest in controlling joint disease, skin involvement, and systemic autoimmune activity.
- Rheumatoid arthritis
- Plaque psoriasis
- Autoimmune inflammatory disease
Its work in this field reflects focus on biologic therapies used in long-term inflammatory disease management.
